Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Neuroscience Solutions in

Neither a doctor nor a teaching hospital

Research payments

$937,795

165 payments

Through program year 2025, Clinical Neuroscience Solutions in is reported as receiving $937,795 in research payments, across 165 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $585,663 70
2024 Research $140,004 34
2023 Research $151,017 46
2022 Research $61,111 15

Breakdown

Who paid Research payments · program years 2022–2025
  1. AbbVie, Inc. $862,378 154 payments
  2. Janssen Research & Development, LLC $75,417 11 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder $256,242 17 payments
  2. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $201,812 55 payments
  3. M24-840 - A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder $124,153 8 payments
  4. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $75,417 11 payments
  5. A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine $56,546 20 payments
  6. Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder $41,430 10 payments
  7. A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects with Major Depressive Disorder $33,096 3 payments
  8. Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder $28,494 3 payments
  9. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $28,087 9 payments
  10. M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $25,221 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record